GlobeNewswire PharmaOriginal article
Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial
Phase 2SION-451SION-2222SION-719Positive
AI Analysis
Summary
Sionna Therapeutics announced plans to advance a dual combination of SION-451 and SION-2222 into Phase 2a proof-of-concept trials based on post hoc analyses from SION-719 showing mean placebo-adjusted sweat chloride reduction of -8.6 mmol/L in cystic fibrosis patients.
Clinical Trial Data
Phase
2a
Outcome Details
Post hoc analyses showed mean placebo-adjusted sweat chloride reduction of up to -8.6 mmol/L consistent with NBD1 biological activity
Importance:6/10
Sentiment:
0.60
Phase 2Cystic FibrosisCombination therapyProof-of-conceptPost hoc analysis
Related Companies
Read the original article
Published by GlobeNewswire Pharma on September 14, 2026 8:01 PM